Skip to main content
. 2024 Aug 9;16(16):2808. doi: 10.3390/cancers16162808

Table 3.

Clinicopathological features according to SMARCB1/INI1 immunohistochemical expression.

SMARCB1/INI1 +
(n = 52)
SMARCB1/INI +/−
(n = 37)
p-Value
Gender (N, %)
Male
Female
28 (53.8%) 23 (62.2%) 0.516
24 (46.2%) 14 (37.8%)
Age (median, range in years) 61.5 (28–86) 59 (17–79) 0.511
Age (N, %)
≤60 years 22 (42.3%) 20 (54.1%) 0.291
>60 years 30 (57.7%) 17 (45.9%)
Tumor size (N, %)
<5 cm 20 (38.5%) 16 (43.2%)
≥5 cm 20 (38.5%) 19 (51.4%) 0.818
Not available 12 (23%) 2 (5.4%)
Tumor localization
Cervical–thoracic–lumbar region 20 (38.5%) 23 (62.2%) 0.033
Sacrococcygeal region 32 (61.5%) 14 (37.8%)
Surgical margin
Adequate 30 (57.7%) 15 (40.5%)
Inadequate 8 (15.3%) 17 (46%) 0.007
Not available 14 (27%) 5 (13.5%)
Ki-67 index
(median, range in percentage)
3 (1–12%) 3 (1–9%) 0.459
Ki-67 index (N, %)
≤3% 26 (50%) 17 (46%)
>3% 24 (46.2%) 13 (35%) 0.817
Not evaluable 2 (3.8%) 7 (19%)

Statistically significant p values are shown in red color.